Last updated: June 7, 2026
Suppliers for Potassium Phosphates in 0.9% Sodium Chloride (IV Infusion): Who Manufactures, Who Distributes, and What to Check Before Sourcing
Potassium phosphates in 0.9% sodium chloride is an IV combination product where sourcing is constrained less by API availability and more by finished-dose sterile manufacturing capacity, container/closure compatibility, and regulatory listing. Buyers typically procure through hospital distributors and GPOs, while direct-customer relationships are usually limited to sterile injectables manufacturers with validated aseptic fill-finish lines and established FDA/USP compliance programs.
If a product listing is required for procurement, the main practical gate is whether the product is shown on the FDA Orange Book (for approved drug products and listed patents) and whether the manufacturer holds the approved NDA/ANDA entry for the specific strengths and container formats.
Who sells potassium phosphates in 0.9% sodium chloride injection to hospitals and distributors?
Featured-snippet style answer: The market is supplied through large hospital distribution networks and licensed sterile-injectables manufacturers, with procurement routed via wholesalers (and often GPO contracts) rather than raw API trading.
Typical distribution channels for IV saline-based phosphate products
- National wholesalers to hospitals: McKesson, Cardinal Health, AmerisourceBergen (often the procurement path in US hospital settings).
- Regional distributors for hospital systems with customized logistics.
- Group Purchasing Organizations for contracted pricing and allocation handling.
Manufacturer vs. private-label practices
- Some sterile injectable products are sold under the finished-dose NDA holder, while others are distributed under contract with wholesalers.
- For product availability, procurement teams track: labeler name, NDC, strength, container size, and package format (vial/bag).
Which companies manufacture potassium phosphates in 0.9% sodium chloride injection?
Featured-snippet style answer: Finished-dose sterile manufacturing is concentrated among a small set of injectable manufacturers; the rest of the supply chain depends on labelers and distributors.
What matters for manufacturer identification
- Product name is often shortened on distributor catalogs, so the sourcing identity should be anchored on:
- Exact strength (potassium phosphate monobasic/dibasic ratio as labeled)
- Final volume and concentration
- NDC and dosage form labeling
- Container type (plastic bag vs vial)
- Sterility assurance method and labeling claims
How to map “suppliers” in practice
- Procurement teams usually map suppliers at two levels:
- “Labeler” on the NDC directory (who appears as the drug labeler)
- Manufacturer of record on the package insert or distributor listing
How do you find the correct suppliers using NDCs for potassium phosphates in 0.9% sodium chloride?
Featured-snippet style answer: Use the NDC as the primary key; product names in catalogs are inconsistent, but NDCs are stable identifiers for the exact strength and presentation.
NDC fields procurement teams should verify
- Labeler name
- Product code
- Package code
- Label description and concentration
- Container size and type
Practical supplier lookup workflow
- Start with the NDC currently used at the hospital or contracting entity.
- Pull the current labeler from the NDC listing.
- Confirm the distributor carrying that NDC and the lead time.
- Check whether any substitutions are being proposed (different concentration or container).
What strength and container formats change supplier availability for potassium phosphates in 0.9% sodium chloride?
Featured-snippet style answer: Supplier availability changes most when the market differentiates by container format and labeled concentration, even when the core ingredients remain the same.
Container-closure and aseptic constraints
- Plastic bags require specific compatibility validation for phosphate salts in saline.
- Vials have different headspace and closure material requirements.
- Differences in fill volume drive line changeover and batch scheduling.
Concentration-specific demand and allocation
- Higher phosphate loadings can be produced in lower-frequency runs.
- Hospitals switching between similar strengths can trigger allocation effects across multiple SKUs.
Are there FDA-approved equivalents (or substitutable products) that different suppliers can provide?
Featured-snippet style answer: Substitution depends on the exact labeled formulation, concentration, and presentation; “potassium phosphates in 0.9% sodium chloride” is not safely substitutable by generic “phosphate in saline” products without label-congruent dosing equivalence.
What to check for substitution risk
- Potassium phosphate form and ratio (monobasic vs dibasic can change osmolality and labeled instructions)
- Final concentrations and total phosphorus expressed by label
- IV compatibility guidance in the prescribing information
- Container volume and infusion rate instructions
What is the Orange Book status of potassium phosphates in 0.9% sodium chloride, and how does it affect supplier sourcing?
Featured-snippet style answer: Orange Book status drives whether there is an approved brand-to-generic landscape; it does not by itself guarantee supply, but it shapes the number of legally marketed competitors.
How Orange Book impacts supplier counts
- If there is a single approved NDA entry with no generic ANDA equivalent, sourcing is naturally constrained.
- If multiple ANDA entries exist, supplier count increases but so does variability in batch availability and lead times.
What procurement teams should do with Orange Book
- Use Orange Book listings to identify:
- NDA/ANDA holders
- Listed drug strengths that correspond to your required NDCs
- Whether listed patents could limit generic entry timing
What generic or alternative suppliers exist, and who is positioned for Paragraph IV (if applicable)?
Featured-snippet style answer: For many niche sterile IV combinations, generic competition is limited or absent; where ANDAs exist, the “Paragraph IV” landscape depends on whether there are unexpired listed patents and FDA approval timing.
Why Paragraph IV matters for supply
- A Paragraph IV challenge can accelerate entry of competing ANDA products post-settlement or post-expiration.
- If there is an ongoing litigation record, settlement terms can delay entry and reduce suppliers.
What manufacturing/IP barriers limit new suppliers for potassium phosphates in 0.9% sodium chloride?
Featured-snippet style answer: The biggest barriers are sterile injectables manufacturing capacity and any formulation, stability, or container-related IP that limits generic replication.
Key barriers by category
- Aseptic fill-finish line availability for sterile IV drugs
- Stability and shelf-life validation for phosphate-saline mixtures in specific containers
- Container-closure compatibility studies
- Regulatory chemistry, manufacturing, and controls (CMC) completeness for ANDA submissions
Which distributors typically carry this IV phosphate-saline product during shortages?
Featured-snippet style answer: During shortages, distribution usually concentrates among major wholesalers with fastest replenishment routes, plus specialty distributors that source from multiple labelers.
Practical shortage sourcing logic
- Major wholesalers rebalance allocations across customers.
- Specialty sterile distributors may broker supply from alternative labelers if equivalents exist by NDC.
Key Takeaways
- Treat “potassium phosphates in 0.9% sodium chloride” as an NDC-specific procurement item; suppliers vary by strength and container format.
- Supplier identification should be done at the labeler and NDC level, not by the shortened product name in catalogs.
- Orange Book status and patent estate shape whether multiple ANDA suppliers can legally market the product.
- Manufacturing and CMC constraints for sterile saline-based phosphate mixtures often limit the number of active finished-dose suppliers, which drives allocation and lead-time risk.
FAQs
1) How do I verify that a substitute “phosphate in saline” product matches potassium phosphates in 0.9% sodium chloride?
Match labeled strength, total volume, phosphate forms/ratio, NDC, and infusion instructions on the prescribing information.
2) What’s the fastest way to identify current suppliers for this IV product?
Use the NDC in the hospital formulary or purchasing contract, then map the labeler and the wholesalers carrying that NDC.
3) Does Orange Book list this combination product, and does it guarantee generic alternatives?
Orange Book lists approved drug products with patent information, but it does not guarantee market supply or availability.
4) What typically drives shortages for sterile IV phosphate-saline products?
Aseptic manufacturing line constraints, batch scheduling, container compatibility validation burden, and limited number of finished-dose labelers.
5) Can different container sizes create separate supplier availability even for the same drug?
Yes. Container/volume differences are typically distinct SKUs with different sourcing and manufacturing batch planning.
References
No sources were provided in the prompt, and no reliable cited materials can be produced without accessing Orange Book/NDC/labeler datasets or product catalog listings.
